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The present study investigates the anxiolytic activity of NR-ANX-C, a standardized polyherbal formulation containing the extracts
of Withania somnifera, Ocimum sanctum, Camellia sinensis, Triphala, and Shilajit in ethanol withdrawal- (EW-) induced anxiety
behavior in rats. Ethanol dependence in rats was produced by substitution of drinking water with 7.5%v/v alcohol for 10
days. Then, ethanol withdrawal was induced by replacing alcohol with drinking water, 12 hours prior to experimentation. After
conﬁrming induction of withdrawal symptoms in the alcohol deprived animals, the anxiolytic activity of the test compound in
graded doses (10, 20, and 40mg/kg) was compared to the standard drug alprazolam (0.08mg/kg) in the elevated plus maze and
bright and dark arena paradigms. In our study, single and repeated dose administration of NR-ANX-C reduced EW-induced
anxiety in a dose-dependent manner. Even though the anxiolytic activity was not signiﬁcant at lower doses, NR-ANX-C at the
highestdosetested(40mg/kg)producedsigniﬁcantanxiolyticactivitythatwascomparabletothestandarddrugalprazolam.Based
on our ﬁndings we believe that NR-ANX-C has the potential to be used as an alternative to benzodiazepines in the treatment of
EW-induced anxiety.
1.Introduction
Ethanol has always occupied an important place in the
history of Human civilization as a social recreational agent
and is the most widely used intoxicating substance in the
world [1–3]. When used in low to moderate quantities,
it relieves anxiety and fosters a feeling of well being and
euphoria. However, excessive alcohol consumption over a
prolonged period of time results in the development of
alcohol dependence [4]. Subsequently, a decline in the
concentration of ethanol in the brain, either due to total
cessation of alcohol consumption or a reduction in intake,
leads to the emergence of abstinence syndrome [5]. Ethanol
withdrawal (EW)/abstinence syndrome is characterized by a
constellation of signs and symptoms, with anxiety being a
hallmark symptom in humans. Along with this, anxiety is
also thought to be the most important negative motivation
to revert to alcohol use [6].
Although agents like benzodiazepines are the mainstay
formanagementofanxietyinEW,theiruseisassociatedwith
side eﬀects like development of sedation, drug dependence,
and so forth, which limits their usefulness in the clinical
setting [7]. Therefore, of late there have been attempts to
develop newer agents from Complimentary and Alternative
systems of Medicine, as these agents are claimed to be
as eﬃcacious as the standard drugs while having minimal
side aﬀects [8]. A number of plants like Ocimum sanctum,
Withania somnifera, and Camellia sinensis have been used
as components of polyherbal formulations in the Ayurvedic
system of medicine for treatment of anxiety disorders. Prac-
titioners of Ayurvedic system of medicine prefer polyherbal
formulations over individual agents as the Ayurvedic treaties
state that a combination of drugs ensures the potentiation of
the therapeutic eﬃcacy of the main drug [9].
The test drug NR-ANX-C is a standardized polyherbal
formulation developed by Natural Remedies Pvt. Ltd,2 Evidence-Based Complementary and Alternative Medicine
Bangalore, India. It is made up of the standardized extracts
of Withania somnifera (Ashwagandha),O c i m u ms a n c t u m
(Tulsi),C a m e l l i as i n e n s i s(Green Tea), Triphala (made up
of fruits of Emblica oﬃcinalis, Terminalia chebula, and
Terminaliabellericans),andShilajit.Therearealargenumber
of experimental studies that have evaluated the central
activityoftheseindividualplantextracts.Withaniasomnifera
[10],O c i m u ms a n c t u m[11], and Camellia sinensis [12]h a v e
been demonstrated to be eﬀective as antistress agents, and
Withania somnifera [13] and Shilajit have been reported
to possess signiﬁcant anxiolytic activity [14]. Previously,
experimental studies carried out in our laboratory have also
shown signiﬁcant anticataleptic [15] and antianxiety [16]
activity in NR-ANX-C. Based on this evidence of central
activity, we hypothesized that NR-ANX-C could also possess
beneﬁcial eﬀects in EW-induced anxiety. In the present
study, we have evaluated the anxiolytic eﬀects of NR-ANX-
C in EW-induced anxiety. Since anxiety in animals is a
subjective state and diﬃcult to quantify [17, 18]w eh a v e
relied on objective animal models for characterization of this
behavioral state.
2. Methods
2.1. Animals. Male Wistar albino rats weighing 180–200g
from our breeding stock were used in the study. They
were housed in groups of three animals per cage and
maintained on a 12:12 hour light/dark cycle at an ambient
temperature of 25 ± 2◦C. The study protocol was approved
by Institutional Animal Ethics Committee, Kasturba Medical
College, Mangalore, and all experiments were carried out in
accordance with “Guidelines for care and use of animals in
scientiﬁc research (Indian National Science Academy 1998,
Revised 2000).”
After acclimatization for seven days, the animals were
housedsingly inmetabolic cages.Theyweredivided intotwo
sets, set one containing six groups and set two containing
ﬁve groups (n = 6). Set one was used for acute study and
set two was used for chronic study. One group from set
one received water and food ad libitum for 10 days and
servedasthenormalcontrol.Thisgroupwastestedunderthe
same conditions and was used to demonstrate the increase in
anxiety behavior after EW in the alcohol-fed animals. The
other ﬁve groups from set one and all groups from set two
received alcohol (7.5% v/v) in drinking water and food ad
libitum for 10 days [19].
2.2. Test Drug. The test drug NR-ANX-C is a standardized
polyherbal formulation (supplied by Natural Remedies Pvt.
Ltd, Bangalore) containing extracts of Withania somnifera
17 percent (aqueous extract of root: total withanolides 2.1%
w/w), Ocimum sanctum 17 percent (70% alcohol extract of
leaves: ursolic acid 2.9% w/w), Camellia sinensis 33 percent
(70% alcohol extract of leaves: total polyphenols 60.1%
w/w), triphala 25 percent (aqueous extract of fruits: total
tannin 33.5% w/w), and shilajit 8 percent (aqueous extract:
fulvic acid 52.6% w/w; humic acid 16.7% w/w).
2.3. Experimental Protocol. The standard drug alprazolam
and test drug NR-ANX-C were freshly prepared in 1%
gum acacia (vehicle) before administration. Five groups of
animalswereusedfromeachset.GroupIreceivedthevehicle
and served as the EW control, Group II received alprazolam
(0.08mg/kg body weight), and Groups III, IV, and V
received NR-ANX-C in doses of 10, 20, and 40mg/kg body
weight, respectively. For acute study, after alcohol exposure
for 10 days, alcohol was withdrawn and substituted with
drinking water 12 hours before starting the experiments.
D e v e l o p m e n to fE Ws y m p t o m si nr a t sw a sc o n ﬁ r m e db y
using the scoring system deﬁned by Gatch and Selvig [20].
After conﬁrmation of EW symptoms, drugs/vehicle was
administered to the respective animals. For chronic study,
drugs/vehicle administration was maintained along with
alcohol exposure for 10 days. As in acute study, alcohol was
withdrawn and substituted with drinking water 12 hours
before starting the experiments.
2.4. Evaluation of Antianxiety Activity. Sixty minutes after
administration of drug/vehicle the animals were sequentially
exposed to the following experimental models of anxiety,
namely,elevatedplusmazeandthebrightanddarkarena.All
apparatus were cleaned thoroughly with alcohol after testing
each animal in order to mask the odour left by the animal.
2.5. Elevated Plus Maze. T h ee l e v a t e dp l u sm a z ei sm a d e
of two open arms (50 × 10cms) and two enclosed arms
(50 × 10 × 40cms) with an open roof, arranged around a
central square, such that arms of same type are opposite to
eachother.Theentiremazeisraised50cmabovetheground.
In this test, the animal was gently placed in the central square
of the maze facing one of the open arms. The number of
entries, time spent, and the number of rears in each type of
arm (open/closed) was recorded for the duration of 5min
[21].
2.6. Bright and Dark Arena. The apparatus consists of an
open-top wooden box with two distinct chambers, namely,
a dark chamber (20 × 30 × 35cms) painted black and
illuminated with a dim red light, and a bright chamber
(30 × 30 × 35cms) painted white and brightly illuminated
with a 100W white light source placed 17cms above the box.
The two chambers are connected by a small open doorway
(7.5cms) located at ﬂoor level in the center of the partition.
Inthistest,theanimalwasplacedinthecenterofthebrightly
lit arena. The total number of entries into bright arena, time
spent in bright arena, number of rears in bright and dark
arena, and the duration of immobility in dark arena were
recorded for a period of 5 minutes [22].
2.7. Statistical Analysis. Statistical analysis was done by using
GraphPad Instat version 3.06 (San Diego, USA). Diﬀerence
betweengroupswascomparedbyOne-wayANOVAfollowed
by Dunnett’s Multiple Comparison test. P<. 05 was consid-
ered signiﬁcant.Evidence-Based Complementary and Alternative Medicine 3
Table 1: EW increases anxiety behavior in elevated plus maze.
Treatment group No. of entries into Total arm
entries
%o fo p e n / t o t a l
arm entries
Time spent in (s) No. of rears in
Open arms Closed arms Open arms Closed arms Open arms Closed arms
Normal control 2.8 ±0.45 .3 ±0.7 8.0 ±1.03 3 .9 ±1.9 32.6 ±5.4 207.6 ±21.82 .6 ± 0.48 .1 ±0.9
EW control 2.3 ±0.45 .1 ±0.9 7.1 ±1.12 7 .9 ±5.4 18.6 ±5.0
∗ 270.0 ±5.5
∗ 1.1 ±0.5
∗ 10.1 ±1.4
Values are mean ± SEM; Statistical analysis by One-way ANOVA followed by Dunnett’s Multiple Comparison test. ∗P<. 05.
Table 2: Acute NR-ANX-C pretreatment reduced EW-induced anxiety behavior in elevated plus maze.
Treatment
group
Number of entries into Total arm
entries
%o fo p e n / t o t a l
arm entries
Time spent in (s) Number of rears in
Open arms Closed arms Open arms Closed arms Open arms Closed arms
EW control 2.3 ±0.45 .1 ±0.97 .1 ±1.12 7 .9 ±5.41 8 .6 ±5.0 270.0 ±5.51 .4 ±0.51 0 .1 ±1.4
Alprazolam
(0.08mg/kg) 6.2 ±0.6
∗∗ 7.3 ±0.21 3 .3 ±0.7
∗∗ 45.2 ±2.3
∗ 81.8 ±12.5
∗∗ 207.0 ±18.5
∗ 5.7 ±0.8
∗∗ 14.3 ±1.0
NR-ANX-C
(10mg/kg) 1.8 ±0.54 .3 ±0.96 .2 ±1.32 7 .2 ±5.62 9 .0 ±10.7 254.0 ±12.91 .7 ±0.57 .5 ±0.7
NR-ANX-C
(20mg/kg) 2.7 ±0.53 .7 ±0.86 .3 ±1.34 2 .8 ±4.25 6 .0 ±17.9 235.0 ±18.52 .3 ±0.81 1 .5 ±1.7
NR-ANX-C
(40mg/kg) 7.0 ±0.6
∗∗ 8.0 ±0.6
∗ 15.0 ±1.1
∗∗ 48.2 ±2.3
∗∗ 73.8 ±13.2
∗ 215.0 ±11.1
∗ 8.7 ±1.2
∗∗ 13.0 ±0.8
Values are mean ± SEM; Statistical analysis by One-way ANOVA followed by Dunnett’s Multiple Comparison test. ∗P<. 05; ∗∗P<. 01.
Table 3: EW increases anxiety behavior in bright and dark arena.
Treatment group No. of entries into
bright arena
Time spent in bright
arena (s)
Rears in bright
arena
Rears in dark
arena
Duration of
immobility (s)
Normal control 2.2 ± 0.6 16.6 ± 1.5 2.5 ± 0.4 9.6 ± 0.7 14.1 ± 1.2
EW control 1.9 ± 0.2 12.4 ± 1.1∗ 1.0 ± 0.3∗ 14.5 ± 0.9∗ 19.8 ± 1.1∗
Values are mean ± SEM; Statistical analysis by One-way ANOVA followed by Dunnett’s Multiple Comparison test. ∗P<. 05.
3. Results
3.1. Acute Study
3.1.1. Elevated Plus Maze. EW produced an increase in
anxiety behavior as demonstrated by a decrease in the
time spent and number of rears in the open arms and an
increase in the time spent and rears in the closed arms by
the EW control animals (Table 1). Acute administration of
alprazolam reversed this behavior and signiﬁcantly increased
the open arm entries, closed arm entries, total arm entries,
percentage of open/total arm entries ratio, time spent in
open arms, and rears in open arms as compared to the
control (Table 2). Even though NR-ANX-C produced a
dose-dependent increase in the anxiolytic behavior, it was
signiﬁcant and comparable to alprazolam only in the highest
dose- (40mg/kg) treated group.
3.1.2. Bright and Dark Arena. EW produced an increase in
behavioral anxiety, as seen by a decrease in the time spent
in the bright arena and an increase in the number of rears
in dark arena and duration of immobility by EW con-
trol animals (Table 3). Acute administration of alprazolam
decreased the anxiety in the treated animals as is evident
by the signiﬁcant reduction in duration of immobility and
increase in time spent in bright arena (Table 4). The test
drug NR-ANX-C also produced a dose-dependent reduction
in anxiety as demonstrated by increase in entries into the
bright arena, time spent in the bright arena, rears, and a
decrease in the duration of immobility. However, change
in these behavioral parameters was signiﬁcant only at the
highest dose (40mg/kg) as compared to the control. At the
highest dose tested (40mg/kg), NR-ANX-C was superior to
alprazolam in ameliorating EW-induced anxiety behavior in
rats.
3.2. Chronic Study
3.2.1. Elevated Plus Maze. Chronic administration of alpra-
zolam was eﬀective in reducing EW-induced anxiety behav-
ior in animals as it signiﬁcantly increased the number of
open arm entries, percentage of open arm/total arm entries,4 Evidence-Based Complementary and Alternative Medicine
Table 4: Acute NR-ANX-C pretreatment reduced EW-induced anxiety behavior in bright and dark arena.
Treatment group Number of entries
into bright arena
Time spent in bright
arena (s)
Rears in bright
arena
Rears in dark
arena
Duration of
immobility (s)
EW control 1.9 ± 0.2 12.4 ± 1.1 1.0 ± 0.3 14.5 ± 0.9 19.8 ± 1.1
Alprazolam (0.08mg/kg) 3.3 ± 0.4 28.6 ± 3.1∗∗ 2.8 ± 0.5 17.0 ± 2.1 3.5 ± 1.3∗∗
NR-ANX-C (10mg/kg) 2.3 ± 0.4 17.0 ± 2.8 1.3 ± 0.4 13.3 ± 1.5 3.2 ± 2.1∗∗
NR-ANX-C (20mg/kg) 2.5 ± 0.3 18.8 ± 4.1 2.7 ± 0.7 17.0 ± 1.9 2.8 ± 1.3∗∗
NR-ANX-C (40mg/kg) 3.8 ± 0.6∗∗ 30.7 ± 3.5∗∗ 3.2 ± 0.5∗ 19.5 ± 2.5 2.7 ± 1.3∗∗
Values are mean ± SEM; Statistical analysis by One-way ANOVA followed by Dunnett’s Multiple Comparison test. ∗P<. 05; ∗∗P<. 01.
Table 5: Chronic NR-ANX-C pretreatment reduced EW-induced anxiety behavior in elevated plus maze.
Treatment group Number of entries into Total Arm
entries
%o fo p e n / t o t a l
arm entries
Time spent in (s) Number of rears in
Open arms Closed arms Open arms Closed arms Open arms Closed arms
EW control 1.6 ± 0.4 5.7 ± 0.8 7.4 ± 1.1 19.8 ± 5.1 15.1 ± 5.7 277.0 ± 5.0 1.1 ± 0.4 10.6 ± 1.3
Alprazolam
(0.08mg/kg) 3.8 ± 0.5∗ 4.8 ± 0.9 8.7 ± 1.1 45.7 ± 4.2∗ 54.7 ± 15.1∗ 234.0 ± 15.1∗ 3.7 ± 0.6∗ 16.2 ± 1.5∗
NR-ANX-C
(10mg/kg) 3.8 ± 0.7∗ 4.8 ± 0.8 8.7 ± 1.3 44.8 ± 4.2∗ 32.2 ± 3.4 262.0 ± 3.8 3.0 ± 0.7 10.8 ± 1.7
NR-ANX-C
(20mg/kg) 4.5 ± 0.6∗ 4.2 ± 0.8 8.7 ± 0.3 53.1 ± 7.9∗ 45.0 ± 10.0∗ 245.0 ± 5.7∗ 3.8 ± 0.8∗ 11.2 ± 0.9
NR-ANX-C
(40mg/kg) 4.8 ± 0.3∗ 4.3 ± 0.7 9.1 ± 0.9 52.74 ± 5.6∗ 49.7 ± 11.1∗ 242.0 ± 16.2∗ 4.8 ±1.1∗ 19.5 ± 0.6∗
Values are mean ± SEM; Statistical analysis by One-way ANOVA followed by Dunnett’s Multiple Comparison test. ∗P<. 05; ∗∗P<. 01.
time spent in open arms, and number of rears, while
reducing the time spent in closed arms, as compared to the
control (Table 5). As in acute study, NR-ANX-C produced
a dose-dependent anxiolytic eﬀect, which was signiﬁcant in
the higher two doses (20 and 40mg/kg) as compared to
control. At the highest dose tested (40mg/kg), NR-ANX-C
wassuperiortothestandarddrugalprazolaminameliorating
EW-induced anxiety behavior in rats.
3.2.2. Bright and Dark Arena. Similar to the results observed
in acute study, chronic administration of alprazolam amelio-
rated EW-induced anxiety behavior in animals as observed
by the signiﬁcant increase in number of entries into the
bright arena, time spent in bright arena, rears, and reduction
in duration of immobility (Table 6). Chronic administration
of NR-ANX-C also produced a dose-dependent inhibition of
anxiety behavior. However, as compared to the EW control,
the anxiolytic activity was signiﬁcant only at the higher
two doses tested (20 and 40mg/kg). At the highest dose
(40mg/kg), NR-ANX-C was comparable to the standard
drug alprazolam in reversing EW-induced anxiety.
4. Discussion
Chronic and excessive ethanol consumption followed by
withdrawal results in the development of abstinence syn-
drome [4, 5]. The most common and prominent feature
of alcohol withdrawal is anxiety, which is also considered
to be the most important negative motivation to revert
to alcohol use [6]. These signs and symptoms of EW
have been attributed to the perturbation of central neu-
rotransmitters and ion channel activity. Evidence indicates
that during ethanol withdrawal there is an upregulation of
excitatory NMDA receptors [23] and a downregulation of
inhibitory GABA-A receptors [24]. Therefore, a drug that
either facilitates the action of GABA or decreases glutamate
activity may be eﬀective in EW-induced anxiety behavior.
Since the extent of anxiety is subjective and often diﬃcult
to quantify, objective animal models have been used to
study the behavioral measures of anxiety during alcohol
withdrawal[18]. The elevated plus maze and bright and dark
arena are the most commonly employed tests for assessing
anxiety like behavior after alcohol withdrawal [25].
In the elevated plus maze, open arms are more fear
provoking than the closed arms and the ratio of entries,
time spent, and rearing behavior in open arms/closed arms
reﬂects the animal’s perception of safety towards closed arms
a n df e a r f u l n e s st o w a r d so p e na r m s[ 20]. Typical anxiolytic
drugs increase the proportion of entries, time spent, rearing
in the open arms, and the ratio of open arm to closed arm
entries. In the present study, EW control animals showed
a reduction in the time spent and rears in the open arms,
but increased the time spent in closed arms as compared
to normal control (nonalcohol-fed) animals in the elevated
plus maze. In the bright and dark arena test, the brightlyEvidence-Based Complementary and Alternative Medicine 5
Table 6: Chronic NR-ANX-C pretreatment reduced EW-induced anxiety behavior in bright and dark arena.
Treatment group Number of entries
into bright arena
Time spent in bright
arena (s)
Rears in bright
arena
Rears in dark
arena
Duration of
immobility (s)
EW control 1.7 ± 0.2 13.9 ± 2.1 1.0 ± 0.3 11.6 ± 1.8 19.6 ±4.9
Alprazolam (0.08mg/kg) 3.0 ± 0.2∗∗ 25.7 ± 1.5∗ 3.0 ± 0.2∗ 20.7 ± 1.6∗∗ 0.9 ± 0.4∗∗
NR-ANX-C (10mg/kg) 2.3 ± 0.2 22.0 ± 3.2 3.0 ± 0.4∗ 12.8 ± 1.4 4.2 ± 2.9∗∗
NR-ANX-C (20mg/kg) 2.7 ± 0.3∗ 27.2 ± 3.3∗ 3.2 ± 0.3∗ 13.2 ± 1.3 2.8 ± 0.7∗∗
NR-ANX-C (40mg/kg) 2.8 ± 0.3∗ 30.7 ± 3.6∗∗ 7.0 ± 0.9∗∗ 18.8 ± 2.5∗ 1.2 ± 4.1∗∗
Values are mean ± SEM; Statistical analysis by One-way ANOVA followed by Dunnett’s Multiple Comparison test. ∗P<. 05; ∗∗P<. 01.
Ethanol withdrawal
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NMDA
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W. somnifera
Shilajit
C. sinensis
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Triphala Increase
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Relapse
Figure 1: EW decreases GABAergic activity and induces anxiogenic mediators in the brain, thus leading to withdrawal anxiety and a relapse
to ethanol consumption. The individual components of NR-ANX-C contribute towards correcting this altered homeostasis, thus alleviating
withdrawal anxiety.
lit area represents a noxious environmental stressor that
inhibits the normal exploratory behavior of rodents and
reduction in the number of entries, time spent, and rearing
in the bright chamber are considered to be a markers
of anxiety [22, 26]. In this model also, the EW control
animals demonstrated a marked reduction in the time spent
and rearing behavior in the bright chamber as compared
to normal control (nonalcohol-fed) animals. Behavioral
changes in both these models suggest that EW augmented
the behavioral inhibition or anxiety like state in the animals.
Both single- and repeated-dose administration of NR-ANX-
C produced a dose-dependent anxiolytic eﬀect in these
experimental models. At the highest dose tested (40mg/kg),
the anxiolytic activity of NR-ANX-C was comparable to the
standard drug alprazolam.
The test drug NR-ANX-C is a standardized polyherbal
formulation containing the extracts of Withania somnifera,
Ocimum sanctum, Camellia sinensis, triphala, and shilajit.
Withania somnifera and its bioactive components have been
shown to have GABA mimetic activity [27, 28]a n dw e
believe that this property might be primarily contributing
towards the anxolytic activity of NR-ANX-C. Additionally,
Withania somnifera has previously been shown to reduce the
levels of tribulin [10], serotonin, and corticotrophin in the
brain [29]. Similarly, shilajit has also been shown to reduce
the brain levels of serotonin [14]. As an increase in the
brain levels of these mediators has been associated with the
development of anxiety, a reduction in their levels by these
two components could have contributed towards ameliora-
tion of the anxiety state. A large number of experimental
studies have reported Ocimum sanctum to possess anxiolytic
activity which has been attributed to it antistressor, cortisol
sparing [30, 31], and antioxidant properties [32]. Along with
neurotransmitters like GABA and serotonin, adenosine has
also been implicated in the development of EW syndrome
and adenosine antagonists have been shown to ameliorate
this state [33]. Camellia sinensis contains methylxanthines
which are central nervous system stimulants and adenosine
antagonists [34]. We believe that these properties could
also have contributed towards the anxiolytic activity of the
polyherbal formulation.
As all the individual constituents of NR-ANX-C have
been shown to possess antianxiety activity, a question arises
as to why a combination has to be used when a higher
dose of any single agent can be used to produce a similar
eﬀect? The answer to this question lies in Ayurvedic treaties,6 Evidence-Based Complementary and Alternative Medicine
which state that drugs when used in combination rather
thanindividuallyensurepotentiationofbeneﬁcialeﬀectsand
amelioration of side eﬀect of the principal drug [9]. This
may be true in this case also, as Withania somnifera, due to
its GABA mimetic activity [27, 28], has sedative properties,
and Camellia sinensis, due to its methyl xanthine content,
has a stimulating eﬀects in brain [35], thus antagonizing the
sedative eﬀect. Additionally, Ocimum sanctum, shilajit, and
Camellia sinensis themselves decrease levels of anxiogenic
mediators in the brain by diﬀerent mechanisms, thus
potentiating the anxiolytic activity of Withania somnifera
(Figure 1). In our study, the anxiolytic activity of NR-ANX-
C (40mg/kg) was comparable to that of the standard drug
alprazolam in both, elevated plus maze and bright and
dark arena paradigms. NR-ANX-C did not produce any
signiﬁcant eﬀect on normal locomotor activity as it did
not increase the duration of immobility in the bright and
dark arena paradigm. Based on the results of our study, we
believe that the polyherbal formulation NR-ANX-C has the
potential to be used as an alternative to benzodiazepines in
the treatment of ethanol withdrawal.
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